Because more than 50% human cancer cells have p53 gene mutations that cause defects in the function of p53 and the lack of functional p53 usually allows cancer cells to resist γ-irradiation or chemotherapeutic agents [7], the highly preferential anti-proliferation effect of NTAPP on cancer cells without functional p53 is of great interest. The gene discussed is TP53; the disease is cancer.